Fosamax Managing Efficacy Plateau: When Alendronate Stops Working and What to Do Next

Alendronate (brand name Fosamax, also sold as an effervescent tablet under the brand Binosto) is an oral nitrogen-containing bisphosphonate approved by the FDA for the treatment and prevention of postmenopausal osteoporosis, treatment of osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget disease of bone. It works by binding to bone mineral and suppressing osteoclast-mediated bone resorption. This article addresses the common oral formulations used for osteoporosis (10 mg daily or 70 mg weekly), not the Paget disease regimen or intravenous bisphosphonates as a class.

The useful question when bone density stops rising on alendronate is not "has the drug stopped working" but "does a flat DXA trend reflect ongoing fracture protection at a stable, elevated bone mass, or does it reflect a correctable problem with adherence, absorption, or an unaddressed secondary cause of bone loss." A bone mineral density (BMD) plateau after several years of continuous bisphosphonate therapy is a pharmacologically expected finding, because once osteoclast activity is maximally suppressed, further BMD gains slow regardless of continued dosing. Genuine treatment failure is a narrower, more serious category: a new fragility fracture after roughly a year or more of confirmed adherent therapy, or a BMD decline that exceeds the measurement precision error of the DXA machine.

What a plateau on alendronate actually means

Alendronate slows bone resorption. In postmenopausal women, this typically produces a measurable rise in BMD during the first several years of treatment, most of it occurring earlier at the hip than at the spine, followed by a flattening as resorption suppression reaches its ceiling. This flattening is a known feature of bisphosphonate pharmacology across the class, described in the original registration trials and their long-term extensions. It does not, by itself, mean the drug has lost effect on fracture risk. A patient whose BMD stabilizes at a level well above pretreatment baseline may still be receiving substantial fracture protection.

Genuine treatment failure is a distinct and narrower concept. Professional society guidance in this space (for example, endocrine society and clinical endocrinology guidelines) generally frames failure as a new fragility fracture occurring after a meaningful period of confirmed adherent therapy, or a BMD decline that exceeds the least significant change for the DXA machine used, typically in the range of a few percentage points at the spine and hip depending on the equipment and technician. Exact numeric thresholds vary by guideline and by imaging center, and a treating clinician should apply the threshold used by the specific DXA facility rather than a single number taken from any one source.

Ruling out a false plateau before assuming the drug has failed

Before concluding that alendronate has stopped working, several correctable explanations should be excluded, because a meaningful share of apparent nonresponse in bisphosphonate-treated patients has been attributed in the compliance literature to missed doses or improper administration rather than true pharmacologic exhaustion, and consulting guidance on what to do after skipping a dose can help rule out this cause.

Adherence and administration technique

Alendronate has low oral bioavailability and a strict administration requirement: taken first thing in the morning on an empty stomach, thirty minutes before any other food, beverage, or medication, with a full glass of plain water, and while remaining upright. Coffee, orange juice, calcium supplements, or lying back down shortly after the dose can meaningfully reduce the small fraction of drug that is absorbed. Persistence with oral bisphosphonates drops substantially over the first year of treatment in published adherence studies, and a clinician evaluating a plateau should ask directly about missed doses, timing, and administration habits, and can cross-check pharmacy refill records where available.

Secondary causes of bone loss

A basic laboratory workup is reasonable before attributing a plateau to drug failure. This typically includes serum 25-hydroxyvitamin D, parathyroid hormone, calcium, thyroid-stimulating hormone, a complete blood count, and a comprehensive metabolic panel, with consideration of 24-hour urine calcium and screening for malabsorptive conditions such as celiac disease when other findings are unexplained. Conditions that can undermine bisphosphonate response include vitamin D insufficiency, primary hyperparathyroidism, hyperthyroidism or thyroid hormone overreplacement, chronic high-dose glucocorticoid exposure (including some inhaled regimens), and heavy alcohol use.

Bone turnover markers as an adherence and absorption check

Serum C-terminal telopeptide (CTX), a marker of bone resorption, can help distinguish adequate drug effect from nonadherence or malabsorption. A markedly suppressed CTX supports that the drug is reaching bone and doing its job; a CTX that remains elevated in a patient reportedly taking alendronate as prescribed raises the likelihood of a missed-dose or absorption problem rather than a true pharmacologic ceiling. Specific numeric cutoffs vary by assay and laboratory, and results should be interpreted against the reference range used by the ordering lab rather than a fixed number taken from an unrelated source.

Dose adjustment: what the label actually allows

Alendronate for osteoporosis is FDA-approved at 10 mg once daily or 70 mg once weekly; the FDA-approved prescribing information for Fosamax describes these as delivering comparable cumulative weekly exposure and comparable BMD effects, so switching between the two schedules is a convenience change, not a dose increase. There is no FDA-approved dose-escalation pathway above 70 mg weekly for osteoporosis. The 40 mg daily dose is approved only for Paget disease of bone; using that dose for osteoporosis is off-label, has not been established as beneficial for osteoporosis fracture reduction in controlled trials, and would be expected to increase gastrointestinal and skeletal adverse-event risk without demonstrated added fracture protection. An effervescent buffered formulation exists for patients with tolerability problems, but it addresses gastrointestinal comfort, not a true efficacy ceiling.

Any change in dose or administration pattern should be discussed with the prescribing clinician. This article does not provide an individualized dosing recommendation.

Drug holidays: the concept, and who it is not for

Because rare adverse events associated with bisphosphonates, atypical femoral fracture and osteonecrosis of the jaw, appear to increase with cumulative duration of use, clinical practice literature has described a "drug holiday" concept: a planned pause in bisphosphonate therapy after a period of continuous treatment, generally discussed after five or more years of oral bisphosphonate use, in patients judged to be at lower or moderate fracture risk. This is a clinical practice strategy described in guideline and task force literature, not an FDA label instruction, and it should be individualized rather than applied as a fixed rule.

Patients generally considered poor candidates for a holiday include those who remain at high fracture risk despite treatment (for example, a hip T-score still in the osteoporotic range), those with a vertebral or hip fracture that occurred during treatment, those with a high estimated 10-year fracture probability, and those on ongoing glucocorticoid therapy.

During a holiday, monitoring typically includes periodic DXA and, where available, bone turnover markers, because residual drug retained in bone continues to provide some fracture protection for a period after stopping, though that protection is not indefinite and appears to wane over time based on long-term extension data from the pivotal bisphosphonate trials. A significant BMD decline or a new fracture during the holiday is generally treated as a signal to resume therapy or switch agents.

When switching drug classes is reasonable

For a confirmed genuine plateau with continued high risk, or true treatment failure, several alternative or step-up agents exist. Each has a distinct FDA-approved population and risk profile, and the choice depends on fracture risk, prior fracture history, cardiovascular history, and patient preference around injection frequency.

• Denosumab is a RANK ligand inhibitor given by subcutaneous injection every six months. It works through a different mechanism than bisphosphonates and has been studied specifically in patients transitioning from oral bisphosphonates, with reported continued BMD gains rather than a plateau over multiple years of use in its long-term extension data. A well-established safety concern is that stopping denosumab is associated with rapid bone loss and a risk of rebound vertebral fractures, so patients who discontinue it are generally transitioned to a bisphosphonate rather than left untreated.
• Teriparatide, a parathyroid hormone analog, and romosozumab, a sclerostin inhibitor, are anabolic agents that build new bone rather than only slowing resorption, and are generally reserved for patients at very high fracture risk. Teriparatide is typically limited to a defined treatment course and followed by an antiresorptive agent to preserve gains. Romosozumab carries an FDA boxed warning regarding cardiovascular risk and is contraindicated in patients with a myocardial infarction or stroke in the preceding year.
• Zoledronic acid, an intravenous bisphosphonate given once yearly, is an option for patients with gastrointestinal intolerance to oral bisphosphonates or absorption concerns, since it bypasses oral absorption entirely, though it remains in the same drug class and mechanism as alendronate.

Effect sizes reported for these agents in their pivotal trials (FREEDOM for denosumab, the teriparatide Fracture Prevention Trial, ARCH for romosozumab, HORIZON-PFT for zoledronic acid, and the original FIT and FLEX trials for alendronate) are widely cited in guideline documents, but the specific percentage reductions attributed to each trial in secondary summaries should be verified against the original peer-reviewed publication before being used in patient-specific counseling. This draft intentionally avoids restating precise trial percentages that could not be independently confirmed against a verified primary source at the time of writing.

Clinician discussion and monitoring framework for a suspected plateau

This is a structured way to bring a suspected plateau to a clinical visit. It is a discussion aid, not a substitute for individualized medical judgment, and every checkpoint below assumes the treating clinician has access to the patient's full history, labs, and imaging.

Checkpoint 1: Confirm the plateau is real, not noise.

• Compare at least two DXA scans on the same machine, same skeletal site, ideally the same technologist.
• Ask whether the change is within the machine's stated precision error before treating it as a decline.
• Escalation trigger: a decline that exceeds the facility's published least significant change, or any new fragility fracture, regardless of BMD trend.

Checkpoint 2: Rule out a false plateau.

• Review actual dosing behavior: timing, position, co-ingested food or drink, and missed doses.
• Check CTX if available, along with vitamin D, PTH, calcium, TSH, and a metabolic panel.
• Escalation trigger: elevated CTX despite reported adherence, or an abnormal secondary-cause lab, both of which point to a fixable problem before any drug change.

Checkpoint 3: Reassess fracture risk and treatment duration.

• Total years on oral bisphosphonate therapy.
• Current T-score, fracture history during treatment, and estimated fracture probability.
• Boundary point: patients at ongoing high risk are generally not candidates for a holiday regardless of duration; this is a site- and guideline-informed judgment, not a fixed cutoff.

Checkpoint 4: Decide holiday, continue, or switch, with the clinician.

• Lower or moderate risk after five-plus years: discuss a monitored holiday versus continued therapy.
• Confirmed adherence with continued decline, or fracture on therapy: discuss switching drug class rather than raising the alendronate dose, since no approved dose-escalation pathway exists.
• Gastrointestinal intolerance without confirmed treatment failure: discuss formulation change or intravenous bisphosphonate before assuming the drug class has failed.

Checkpoint 5: Set the next monitoring point before ending the visit.

• DXA interval agreed upon (commonly one to two years during active reassessment, longer during a stable holiday).
• Turnover marker recheck timing, if used, generally sooner than the next DXA since markers can shift within months.
• Clear instruction on what finding should trigger an earlier visit: a fall, a new fracture, new back pain, or a height loss the patient notices.

When this framework does not apply: patients with secondary osteoporosis causes that are still being actively treated, patients on concurrent glucocorticoids, patients who have not yet completed a baseline workup, and any patient whose case involves a recent fracture requiring urgent orthopedic evaluation rather than routine reassessment.

What is established, what is plausible, and what is not established

Established: bisphosphonates including alendronate produce a rise in BMD that slows over years of continuous use as an expected pharmacologic pattern; the FDA-approved osteoporosis dosing tops out at 70 mg weekly with no approved higher dose; denosumab, teriparatide, romosozumab, and zoledronic acid each have FDA-approved indications relevant to patients who have not responded adequately to oral bisphosphonates; stopping denosumab carries a documented rebound fracture risk that requires a follow-on antiresorptive.

Plausible but not fully settled for an individual patient: the ideal duration of a bisphosphonate drug holiday, the precise BMD or turnover-marker threshold that should trigger restarting therapy, and how much residual fracture protection persists after stopping alendronate in any given patient, since this varies with total treatment duration and bone turnover.

Not established from the material available here: any specific numeric fracture-reduction percentage attributed to a named trial should be treated as unverified until checked against the original publication; this article intentionally does not restate those figures as confirmed facts.

When to seek urgent care rather than wait for the next scheduled visit

A new fracture after a fall, new or worsening thigh or groin pain (a possible warning sign of atypical femur fracture), jaw pain or exposed bone after a dental procedure (a possible sign of osteonecrosis of the jaw), or a fall with suspected fracture all warrant prompt medical evaluation rather than waiting for a routine follow-up.